Cyclopharm Secures U.S. Patent Extension for Technegas® to 2031

Cyclopharm Limited ( (AU:CYC) ) just unveiled an announcement.

Cyclopharm Limited has secured a five-year patent extension for its Technegas® Kit in the United States, extending exclusivity until 2031. This extension provides a significant competitive advantage in the U.S. market, allowing Cyclopharm to capitalize on the commercial and clinical potential of Technegas® without the threat of generic competition. The extension underscores the strong clinical profile of Technegas® and supports Cyclopharm’s strategic efforts to expand its market presence and innovation in pulmonary imaging technologies.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community. The company focuses on improving patient care outcomes through its core product, Technegas®, which is used in functional lung ventilation imaging. Technegas® is a radioactive diagnostic agent that aids in the visualization of pulmonary ventilation and evaluation of pulmonary embolism, with applications extending to other respiratory conditions.

Average Trading Volume: 93,964

Technical Sentiment Signal: Sell

Current Market Cap: A$116.7M

See more insights into CYC stock on TipRanks’ Stock Analysis page.